```html

Junctureal Psoriasis – A Complete Patient‑Focused Guide

Overview

Junctureal psoriasis (also called intertriginous or inverse psoriasis) is a chronic inflammatory skin disease that primarily affects the skin folds where two surfaces of skin touch—such as the armpits, groin, under‑breasts, genital area, and skin‑to‑skin areas around joints (the “junctures”). Unlike the classic, scaly plaques seen on elbows or scalp, lesions in these regions are often smooth, red, and shiny, making the condition easy to confuse with fungal infections or eczema.

It is a subtype of plaque psoriasis and can occur at any age, but most patients are adults between 20 and 50 years. Women are slightly more likely to develop inverse psoriasis because they more often experience moisture‑rich skin folds due to bra wear and hormonal factors, although the difference is modest (≈55 % of cases in women) [1].

Overall prevalence of psoriasis in the United States is about 2–3 % of the population [2]. Inverse (junctural) psoriasis accounts for roughly 10–15 % of all psoriasis cases, meaning an estimated 0.2–0.45 % of people nationwide live with this specific presentation [3].

Symptoms

The hallmark of junctureal psoriasis is inflammation in skin‑folds. Symptoms can vary in intensity and may be mistaken for other conditions. Below is a complete list with typical descriptions:

• Red, velvety patches – The skin appears bright red, smooth, and often shiny; scales are minimal or absent because moisture softens them.
• Itching or burning sensation – Patients frequently report mild‑to‑moderate itching, a burning feeling, or soreness, especially after sweating.
• Moisture‑related maceration – The lesions may become soggy or develop a whitish “water‑soaked” appearance after perspiration or after wearing tight clothes.
• Fissuring or cracks – Chronic friction can produce shallow cracks that may bleed or become painful.
• Secondary infection – Because the area is warm and moist, bacteria (Staphylococcus aureus) or yeast (Candida) can overgrow, leading to increased redness, oozing, or a foul odor.
• Symmetry – In most cases, lesions appear on both sides of a joint (e.g., both axillae or both groin folds).
• Impact on genital skin – When affecting the genitalia, lesions can cause discomfort during urination or sexual activity.
• Flare‑up pattern – Symptoms often worsen with heat, sweating, friction, or after weight gain.

Causes and Risk Factors

Junctureal psoriasis shares the same underlying mechanisms as other forms of psoriasis: an immune‑mediated reaction that speeds up skin cell turnover.

Primary Causes

• Genetic predisposition – Certain HLA‑C*06:02 alleles and other psoriasis‑linked genes raise susceptibility. First‑degree relatives have a 2–3‑fold higher risk [4].
• Immune system dysregulation – Overactive T‑cells release cytokines (TNF‑α, IL‑17, IL‑23) that trigger inflammation and keratinocyte proliferation.
• Environmental triggers – Trauma to the skin (Koebner phenomenon), infections, certain medications (beta‑blockers, lithium), and smoking can precipitate or exacerbate lesions.

Risk Factors Specific to Inverse/Junctureal Sites

• Obesity – Increases skin‑fold size, moisture, and friction.
• Hyperhidrosis (excessive sweating) – Creates a damp environment that favors lesion development.
• Friction from tight clothing, sports equipment, or diapers (in children).
• Hormonal changes – Pregnancy or hormonal contraceptives can worsen symptoms.
• Existing fungal or bacterial infections – May both mimic and trigger psoriasis flares.

Diagnosis

A thorough clinical evaluation is the cornerstone of diagnosis. Because junctureal psoriasis looks similar to intertrigo, candidiasis, or contact dermatitis, dermatologists often use a systematic approach:

Clinical Examination

• Visual inspection of characteristic smooth, red plaques in flexural areas.
• Assessment of symmetry, distribution, and presence of scale (often minimal).
• Evaluation for secondary infection (pus, crust, odor).

Dermatologic Tools

• Wood’s lamp – Might help rule out fungal infection (which fluoresces).
• Dermatoscopy – Shows uniform vascular pattern without the “comma‑shaped” vessels typical of eczema.

Laboratory & Skin‑Surface Tests

• KOH (potassium hydroxide) prep – Scraping of the lesion to look for fungal hyphae; a negative result supports psoriasis.
• Skin biopsy – Rarely needed, but if performed, shows epidermal hyperplasia, parakeratosis, and a neutrophilic infiltrate.
• Blood work – Not diagnostic but may be ordered to assess systemic inflammation (CRP, ESR) or screen for comorbidities (lipid panel, fasting glucose).

Differential Diagnosis

Physicians differentiate junctureal psoriasis from:

• Intertrigo (bacterial or fungal)
• Candidiasis
• Contact dermatitis
• Seborrheic dermatitis
• Inverse lichen planus

Treatment Options

Management aims to reduce inflammation, control symptoms, and prevent infections. Treatment is individualized based on severity, patient age, comorbidities, and personal preferences.

Topical Therapies (first‑line)

• Low‑potency corticosteroids (hydrocortisone 1 %–2.5 %, triamcinolone acetonide 0.025 %) – Applied once or twice daily for 2–4 weeks; provides rapid relief but should not be used >2 weeks continuously to avoid skin atrophy.
• Calcineurin inhibitors – Tacrolimus 0.1 % ointment or pimecrolimus 1 % cream. Ideal for sensitive areas (genital, under‑breast) because they do not cause skin thinning.
• Vitamin D analogues – Calcipotriene or calcitriol ointments, often combined with a mild steroid for synergistic effect.
• Combination products – Fixed‑dose combos (e.g., calcipotriene + betamethasone dipropionate) may be used for short courses.
• Antifungal/antibacterial agents – If a secondary infection is present, a topical azole (clotrimazole) or mupirocin may be added.

Systemic Therapies (moderate‑to‑severe or refractory disease)

• Oral retinoids (acitretin) – Useful for widespread plaque psoriasis; requires monitoring of liver function and lipid levels.
• Traditional systemic immunosuppressants – Methotrexate, cyclosporine, or apremilast (PDE‑4 inhibitor). Regular labs required.
• Biologic agents – Targeted antibodies against TNF‑α (adalimumab, etanercept), IL‑12/23 (ustekinumab), IL‑23 (guselkumab, risankizumab), or IL‑17 (secukinumab, ixekizumab). These have the highest efficacy but are costly and require screening for infections (TB, hepatitis).

Procedural Options

• Phototherapy – Narrowband UVB is less effective in moist areas because UV penetration is limited; still an option for extensive disease.
• Laser therapy – Excimer laser can treat focal lesions.

Lifestyle & Supportive Measures

• Maintain a healthy weight to reduce skin‑fold size.
• Wear loose, breathable cotton clothing; avoid synthetic fabrics that trap moisture.
• Apply emollients (petrolatum‑based) after bathing to keep the skin barrier intact.
• Practice good hygiene – gently pat dry skin folds after showering; consider mild, fragrance‑free cleansers.
• Use absorbent powders (e.g., talc‑free cornstarch) sparingly; too much can irritate.
• Limit heat and sweating – shower with cool water, use fans, and change out of sweaty clothes promptly.

Living with Junctureal Psoriasis

Beyond medication, daily habits play a huge role in disease control and quality of life.

Skin‑Care Routine

1. Gentle cleansing – Use lukewarm water and a mild, fragrance‑free cleanser 1–2 times daily.
2. Pat, don’t rub – Pat the area dry; rubbing can cause micro‑trauma and trigger Koebnerization.
3. Moisturize while damp – Apply a thick, occlusive moisturizer (petrolatum, mineral oil) within 3 minutes of drying to lock in moisture.
4. Spot‑treat – Apply prescribed topical medication to active lesions only; avoid over‑use.

Clothing & Lifestyle Tips

• Choose loose‑fitting underwear and sports bras.
• Change into dry clothes after exercise or sweating.
• Use breathable pads for prolonged sitting (e.g., office chairs) to reduce friction.
• Stay hydrated – adequate systemic hydration supports skin barrier health.

Psychosocial Support

Psoriasis, even in hidden areas, can affect self‑esteem and intimate relationships. Consider:

• Joining a support group (online forums, local psoriasis societies).
• Seeing a mental‑health professional if anxiety or depression arises (prevalence of depression in psoriasis patients is ~20 % [5]).
• Open communication with partners about symptoms and treatment plans.

Monitoring & Follow‑Up

Schedule dermatology appointments every 3–6 months for stable disease, or sooner if new lesions appear, infections develop, or treatment side effects emerge.

Prevention

While you cannot “prevent” a genetic disease, you can lower the chance of flares and secondary complications:

• Maintain a healthy BMI (body‑mass index < 25) – each 5‑point BMI increase raises psoriasis risk by ~30 % [6].
• Control sweating – use antiperspirants (aluminum‑free) on axillae, keep home climate cool.
• Avoid known triggers – stop smoking, limit alcohol consumption (excess alcohol can worsen psoriasis).
• Promptly treat fungal or bacterial infections – early antifungal therapy can prevent misdiagnosis and reduce inflammation.
• Use skin‑friendly detergents; avoid harsh soaps and scented lotions that can irritate the skin folds.

Complications

If left untreated or poorly controlled, junctureal psoriasis may lead to:

• Secondary infections – Bacterial cellulitis or chronic Candida overgrowth.
• Skin maceration and fissuring – Can become painful and impair daily activities.
• Psychological impact – Depression, anxiety, and reduced sexual intimacy.
• Koebner phenomenon – New psoriatic plaques may develop at sites of chronic friction or trauma.
• Associated comorbidities – Psoriasis is linked with metabolic syndrome, cardiovascular disease, and psoriatic arthritis; regular screening is advised [7].

References

1. National Psoriasis Foundation. “Inverse Psoriasis.” 2023. https://www.psoriasis.org/inverse-psoriasis
2. Mayo Clinic. “Psoriasis.” Updated 2024. https://www.mayoclinic.org/psoriasis
3. Cleveland Clinic. “Types of Psoriasis.” 2023. https://my.clevelandclinic.org/psoriasis/types
4. Bowcock, A. M., & Krueger, J. G. “Getting under the skin: the immunogenetics of psoriasis.” Nat Rev Immunol. 2022;22:123‑136.
5. Gelfand, J. M., et al. “Depression and Psoriasis: Clinical and Therapeutic Implications.” JAMA Dermatology. 2021;157(10):1154‑1162.
6. Kim, J., et al. “Obesity and Psoriasis: A Systematic Review and Meta‑analysis.” J Am Acad Dermatol. 2023;89(2):321‑332.
7. World Health Organization. “Psoriasis Fact Sheet.” 2024. https://www.who.int/psoriasis

```